$118 Million is the total value of Euclidean Capital LLC's 10 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 9.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PMVP | PMV PHARMACEUTICALS INC | $33,301,000 | -31.6% | 2,336,909 | 0.0% | 28.32% | +0.2% | |
| ME | 23ANDME HOLDING CO | $25,403,000 | -35.2% | 10,243,122 | 0.0% | 21.61% | -5.2% | |
| FHTX | FOGHORN THERAPEUTICS INC | $17,153,000 | -10.7% | 1,261,261 | 0.0% | 14.59% | +30.7% | |
| ALEC | ALECTOR INC | $9,966,000 | -28.7% | 980,894 | 0.0% | 8.48% | +4.3% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $9,572,000 | -15.9% | 746,674 | 0.0% | 8.14% | +23.0% | |
| RAPT | RAPT THERAPEUTICS INC | $7,900,000 | -17.0% | 432,900 | 0.0% | 6.72% | +21.5% | |
| TENAYA THERAPEUTICS INC | $5,155,000 | -52.2% | 915,705 | 0.0% | 4.38% | -30.1% | ||
| FFBC | FIRST FINL BANCORP OH | $3,367,000 | -15.8% | 173,576 | 0.0% | 2.86% | +23.2% | |
| ORIC | ORIC PHARMACEUTICALS INC | $3,349,000 | -16.1% | 747,550 | 0.0% | 2.85% | +22.8% | |
| SURROZEN INC | $2,409,000 | -0.3% | 802,963 | 0.0% | 2.05% | +45.8% | ||
| COIN | Exit | COINBASE GLOBAL INC | $0 | – | -46,922 | -100.0% | -5.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PMV PHARMACEUTICALS INC | 12 | Q3 2023 | 54.4% |
| FOGHORN THERAPEUTICS INC | 12 | Q3 2023 | 16.4% |
| NGM BIOPHARMACEUTICALS INC | 12 | Q3 2023 | 14.5% |
| ALECTOR INC | 12 | Q3 2023 | 11.5% |
| RAPT THERAPEUTICS INC | 12 | Q3 2023 | 9.7% |
| ORIC PHARMACEUTICALS INC | 12 | Q3 2023 | 10.0% |
| TENAYA THERAPEUTICS INC | 9 | Q3 2023 | 9.9% |
| FIRST FINL BANCORP OH | 9 | Q4 2022 | 3.9% |
| SURROZEN INC | 9 | Q3 2023 | 2.9% |
| 23ANDME HOLDING CO | 7 | Q3 2023 | 27.2% |
View Euclidean Capital LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PMV Pharmaceuticals, Inc. | February 14, 2022 | 2,336,909 | 5.1% |
View Euclidean Capital LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2023-12-01 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Euclidean Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.